Literature DB >> 10989262

Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia.

C R Breese1, M J Lee, C E Adams, B Sullivan, J Logel, K M Gillen, M J Marks, A C Collins, S Leonard.   

Abstract

Previous studies have suggested that an abnormality in neuronal nicotinic acetylcholine receptor expression or function may be involved in the neuropathophysiology of schizophrenia. [(3)H]-nicotine and [(3)H]-epibatidine binding were compared in postmortem brain from control and schizophrenic subjects with varying smoking histories. In control subjects, increased receptor binding was seen in hippocampus, cortex, and caudate with increasing tobacco use. In contrast, schizophrenic smokers had reduced nicotinic receptor levels in these brain regions compared to control smokers. Chronic haloperidol and nicotine treatment, in the rat, was used to assess neuroleptic effects on receptor up-regulation by nicotine. A significant increase in cortical nicotinic receptors was seen in both nicotine treated as well as haloperidol and nicotine co-treated animals, suggesting that the abnormal regulation of high affinity neuronal nicotinic receptors in schizophrenics following nicotine use was not related to chronic neuroleptic treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10989262     DOI: 10.1016/S0893-133X(00)00121-4

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  118 in total

Review 1.  Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue.

Authors:  B Dean
Journal:  Postgrad Med J       Date:  2002-03       Impact factor: 2.401

Review 2.  Cognitive effects of nicotine: genetic moderators.

Authors:  Aryeh I Herman; Mehmet Sofuoglu
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

3.  Positron emission tomography experience with 2-[¹⁸F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸F]FA) in the living human brain of smokers with paranoid schizophrenia.

Authors:  James Robert Brašić; Nicola Cascella; Anil Kumar; Yun Zhou; John Hilton; Vanessa Raymont; Andrew Crabb; Maria Rita Guevara; Andrew G Horti; Dean Foster Wong
Journal:  Synapse       Date:  2011-12-29       Impact factor: 2.562

4.  Genetic interaction between alpha4 and beta2 subunits of high affinity nicotinic receptor: analysis in schizophrenia.

Authors:  Vincenzo De Luca; Sophocles Voineskos; Greg Wong; James L Kennedy
Journal:  Exp Brain Res       Date:  2006-04-25       Impact factor: 1.972

5.  Nicotinic acetylcholine receptor expression on B-lymphoblasts of healthy versus schizophrenic subjects stratified for smoking: [3H]-nicotine binding is decreased in schizophrenia and correlates with negative symptoms.

Authors:  Christian Luckhaus; Uwe Henning; Stefano Ferrea; Francesco Musso; Arian Mobascher; Georg Winterer
Journal:  J Neural Transm (Vienna)       Date:  2011-12-11       Impact factor: 3.575

Review 6.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 7.  Epigenetic GABAergic targets in schizophrenia and bipolar disorder.

Authors:  A Guidotti; J Auta; Y Chen; J M Davis; E Dong; D P Gavin; D R Grayson; F Matrisciano; G Pinna; R Satta; R P Sharma; L Tremolizzo; P Tueting
Journal:  Neuropharmacology       Date:  2010-11-11       Impact factor: 5.250

Review 8.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

9.  Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.

Authors:  Salma R I Ribeiz; Débora P Bassitt; Jony A Arrais; Renata Avila; David C Steffens; Cássio M C Bottino
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

10.  Single photon emission computed tomography experience with (S)-5-[(123)I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers.

Authors:  James Robert Brasić; Yun Zhou; John L Musachio; John Hilton; Hong Fan; Andrew Crabb; Christopher J Endres; Melvin J Reinhardt; Ahmet S Dogan; Mohab Alexander; Olivier Rousset; Marika A Maris; Jeffrey Galecki; Ayon Nandi; Dean F Wong
Journal:  Synapse       Date:  2009-04       Impact factor: 2.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.